Guardion Health Sciences, Inc.   Report issue

For profit Phase 4
Founded: San Diego CA United States (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2018
NCT03946085
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Guardian Health Sciences, Inc. | Guardion Health Sciences, Inc.

Active Ingredients

Drugs in Phase 4 Trials (2)

carotenoid (2 trials)

dorzolamide (trusopt) (1 trial)

Drugs in Other Trials (2)

multivitamins (1 trial)

omega-3 fatty acids (Omacor) (1 trial)

Indications

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 4